ABSTRACT

Infliximab is an anti-tumor necrosis factor alpha agent, which is indicated for the treatment of resistant ankylosing spondylitis (AS). We presented a patient with AS who developed ventricular tachycardia after premature cessation of infliximab. Ventricular tachycardia did not recur after restarting of infliximab treatment. This case report remarked the significance of the suppression of inflammation in AS since the subclinical ventricular involvement may potentially lead to the fatal arrhythmias.

Keywords: Arrhythmia, Arthritis, Seronegative Spondyloarthropathy, Syncope, Tumor Necrosis Factor Alpha